Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 6, 2007, Pages 471-478

  Singer, Elisabeth ^a,b   Gschwantler, Michael ^a,c   Plattner, Dina ^a   Kriwanek, Stephan ^a   Armbruster, Christian ^d   Schueller, Johann ^a   Feichtinger, Hans ^a   Roka, Rudolf ^a   Moeschl, Peter ^a   Weiss, Werner ^a   Kroiss, Alois ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c WILHELMINEN HOSPITAL   (Austria)

^d KA Floridsdorf ^*  (Austria)

Author keywords

18F fluordeoxyglucose; Mass forming pancreatitis diagnosis; Pancreatic cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

ADULT; AGED; ARTICLE; AUTOPSY; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRYSTAL; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOCRINE TUMOR; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FILTER; FOLLOW UP; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS SCINTISCANNING; PANCREATITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HUMANS; MALE; MIDDLE AGED; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 34248187073     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328011741d     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts and figures: 2003; Yearly report pp. 1-50.
2. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumour marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988; 33:1223.
3. Frieß H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36:771-777.
4. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000; 24:1121-1129.
5. Ho CL, Dehdashti F, Griffith LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996; 20:363-369.
6. Zimny M, Bares R, Faß J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24:678-682.
7. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
8. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are introduced by ras or src oncogenes. Science 1987; 235:1492-1495.
9. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by PSV rapidly increases glucose transporter gene transcription. Science 1987; 235:1495-1498.
10. 14C-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916.
11. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, et al. Labelled 2-deoxy-D-glucose analogues. 18F-labeled 2-deoxy-2-fluoro- D-glucose, 2-deoxy-2-fluoro-D-mannose, 14C-2-deoxy-2-fluoro- D-glucose. J Labelled Comp Raiopharm 1978; 14:175.
12. Som P, Atkins HL, Bandoypadhyay D, Fowler S, MacGregor RR, Matusi K, et al. A fluorinated glucose analogue, 2-fluoro-2-deoxy-D- glucose (F18): nontoxic tracer for rapid tumour detection. J Nucl Med 1980; 7:670-675.
13. Wahl RL. Targeting glucose transporters for tumour imaging: 'sweet' idea, 'sour' result. J Nucl Med 1996; 37:1038-1041.
14. Bares R, Dohmen BM, Cremerius U, Faß J, Teusch M, Büll U. Results of positron emission tomography with fluorine-18-labelled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma [in German]. Radiologe 1996; 36:435-440.
15. Stollfuss J, Glatting G, Friess H, Kocher F, Beger H, Reske S. 2-(flourine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195:339-344.
16. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192:79-86.
17. Zimny M, Kaiser HJ, Cremerius U, Reinartz P, Schreckenberger M, Sabri O, et al. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D- glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection. Eur J Nucl Med 1999; 26:818-823.
18. Stokkel MPM, Moons KGM, Ten Broek FW, Van Rijk PP, Hordijk GJ. 18F-Fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumours in case of head and neck cancer. Cancer 1999; 86:2370-2377.
19. Coleman RE, Laymon CM, Turkington TG. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET and dedicated PET. Radiology 1999; 210:823-828.
20. Lytras D, Connor S, Bosonnet L, Jayan R, Evans J, Hughes M, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005; 22:55-62.
21. Giorgi MC, Cunha RM, Soares J, Izaki M, Saito ET, de Barros M, et al. Dual-head gamma camera coincidence imaging in pancreatic cancer. Rev Esp Med Nucl (Spain) 2004; 23:90-94.
22. Rasmussen I, Sorensen J, Langstrom B, Haglund U. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses? Scand J Surg 2004; 93:191-197.
23. Nishijima KI, Kuge Y, Tsukamoto E, Seki KI, Ohkura K, Magata Y, et al. Increased [18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) yield with recycled target [18O]water: factors affecting the [18]FDG yield. Appl Radiat Isot 2002; 57:43-49.
24. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89:2547-2554.
25. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, et al. 18fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surgery 1999; 229:729-739; discussion 737-738.
26. Diedrichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, et al. Values and limitations of F18-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20:109-116.
27. Keogan MT, Baker ME. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR 1998; 171:1565-1570.
28. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluordeoxyglucose positron emission tomography in the management of patients with cystic tumours of the pancreas. Ann Surg 2001; 234:675-680.
29. Boren EL, Delbecke D, Patton JA, Sandler MP. Comparison of FDG PETand positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. Eur J Nucl Med 1999; 26:379-387.
30. Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 2005; 9:22-29.
31. Kouwen M, Jansen J, Goor H, de Castro S, Oyen W, Drenth J. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005; 32:399-404.
32. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D- glucose. J Nucl Med 1978; 19:1154-1161.
33. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Routsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34:1-6.
34. Wahl RL, Henry CA, Ethrer SP. Serum glucose: effects on tumour and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxyglucose in rodents with mammary carcinoma. Radiology 1992; 183:643-647.
35. Langen KJ, Braun U, Rota Kops E. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355-359.
36. Zhuang HM, Cortes-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martinez-Lazaro R, et al. Effect of hyperglycaemia on FDG-uptake by inflammatory and malignant lesions. Nucl Med Commun 2001; 22:1123-1128.
37. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 2001; 28:730-735.
38. Torizuka T, Fisher SJ, Wahl RL. Insulin induced hypoglycaemia decreases uptake of 2-F18-fluorodeoxy-D-glucose into experimental mammary carcinoma. Radiology 1997; 203:169-172.
39. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39:1030-1033.
40. Johnson R. Pancreatic cancer. Hepatogastroenterol 1995; 42:294-297.
41. Schmied BM, Ulrich AB, Matsuzaki H, Li C, Friess H, Bochler MW, et al. Alterations of the Langerhans islets in pancreatic cancer patients. Int J Pancreatol 2000; 28:187-197.
42. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoural distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
43. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259-264.
44. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28:700-706.
45. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schäfer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001; 22:1277-1285.
46. Kunze WD, Baehre M, Richter E. PET with dual-head coincidence camera: spatial resolution, scatter fraction and sensitivity. J Nucl Med 2000; 41:1067-1074.
47. Nitzsche E, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002; 29:237-242.
48. Delbeke D, Sandler MP. The role of hybrid cameras in oncology. Semin Nucl Med 2000; 30:268-280.
49. Stokkel MPM, De Klerk JHM, Zelissen PMJ, Koppeschaar HPF, van Rijk PP. Fluorine-18 Fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999; 26:1606-1609.
50. Hamberg L, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.